Valuation: Agios Pharmaceuticals, Inc.

Market Cap 2.22B 1.98B 1.83B 1.66B 3.12B 209B 3.16B 21.96B 8.62B 110B 8.33B 8.15B 351B P/E 2026 *
-6.45x
P/E 2027 * -9.87x
Enterprise Value 2.09B 1.86B 1.72B 1.56B 2.93B 197B 2.97B 20.64B 8.1B 103B 7.83B 7.66B 330B EV / Sales 2026 *
11.8x
EV / Sales 2027 * 6.37x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day+1.47%
1 week+20.05%
Current month+11.82%
1 month+9.51%
3 months-0.48%
6 months+41.42%
Current year+36.59%
1 week 31.16
Extreme 31.16
37.58
1 month 29.67
Extreme 29.67
37.58
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 07/08/2022
Director of Finance/CFO 51 25/09/2022
Chief Tech/Sci/R&D Officer 47 31/08/2021
Director TitleAgeSince
Director/Board Member 66 08/12/2014
Director/Board Member 73 22/06/2015
Director/Board Member 73 26/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
04/08/26 Sell

Chief Technology Officer

-30,000 0.0504%
08/07/26 Free

Director

2,894 0.0049%
01/07/26 Exercice

Chief Technology Officer

20,757 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
+1.47%+20.05%-14.43%+73.90% 2.22B
-0.21%-4.43%+44.40%+74.13% 66.22B
-2.70%+0.95%+7.98%+69.84% 55.2B
+0.37%+3.81%+11.93%+91.33% 52.79B
+3.28%+5.58%+26.51%+50.05% 45.53B
+0.51%+9.95%+22.40%+133.92% 43.94B
-1.15%+0.39%+263.21%+594.60% 41.64B
+0.10%+9.90%+16.11%+59.33% 34B
-8.38%-6.95%+26.35%-1.93% 25.84B
+0.53%+4.19%+37.24%+27.11% 23.51B
Average -0.61%+5.67%+44.17%+117.23% 39.09B
Weighted average by Cap. -0.55%+3.82%+49.21%+126.07%

Financials

2026 *2027 *
Net sales 178M 159M 147M 133M 250M 16.8B 253M 1.76B 691M 8.83B 668M 654M 28.14B 347M 309M 286M 259M 488M 32.75B 494M 3.43B 1.35B 17.22B 1.3B 1.27B 54.86B
Net income -342M -305M -282M -255M -481M -32.27B -487M -3.38B -1.33B -16.96B -1.28B -1.26B -54.05B -233M -207M -192M -174M -327M -21.95B -331M -2.3B -903M -11.54B -873M -855M -36.77B
Net Debt -133M -119M -110M -99.62M -188M -12.59B -190M -1.32B -518M -6.62B -501M -490M -21.09B -18.27M -16.28M -15.07M -13.64M -25.7M -1.72B -26.01M -181M -70.92M -906M -68.54M -67.11M -2.89B
Projected Income Statement - Annual - Agios Pharmaceuticals, Inc.
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
21/10/26 US$37.18 +1.47% 849,888
20/10/26 US$36.64 +4.99% 1,518,815
19/10/26 US$34.90 +11.43% 1,973,686
16/10/26 US$31.32 -3.09% 952,684
15/10/26 US$32.32 +4.36% 2,048,391
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Agios Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
37.18USD
Average target price
46.00USD
Spread / Average Target
+23.72%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Agios Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. AGIO Stock